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Abstract Renal stone disease (nephrolithiasis) affects 3–5%
of the population and is often associated with hypercalciuria.
Hypercalciuric nephrolithiasis is a familial disorder in over
35%ofpatientsandmayoccurasamonogenicdisorderthatis
more likely to manifest itself in childhood. Studies of these
monogenicformsofhypercalciuricnephrolithiasisinhumans,
e.g. Bartter syndrome, Dent’s disease, autosomal dominant
hypocalcemic hypercalciuria (ADHH), hypercalciuric neph-
rolithiasis with hypophosphatemia, and familial hypomagne-
semia with hypercalciuriahave helped toidentify a number of
transporters, channels and receptors that are involved in
regulating the renal tubular reabsorption of calcium. Thus,
Bartter syndrome, an autosomal disease, is caused by
mutations of the bumetanide-sensitive Na–K–Cl (NKCC2)
co-transporter, the renal outer-medullary potassium (ROMK)
channel, the voltage-gated chloride channel, CLC-Kb, the
CLC-Kb beta subunit, barttin, or the calcium-sensing receptor
(CaSR). Dent’sdi se as e,anX- li nk eddi so rd erch ar ac te ri ze dby
low molecular weight proteinuria, hypercalciuria and neph-
rolithiasis, is due to mutations of the chloride/proton
antiporter 5, CLC-5; ADHH is associated with activating
mutations of the CaSR, which is a G-protein-coupled
receptor; hypophosphatemic hypercalciuric nephrolithiasis
associated with rickets is due to mutations in the type 2c
sodium–phosphate co-transporter (NPT2c); and familial
hypomagnesemia with hypercalciuria is due to mutations of
paracellin-1, which is a member of the claudin family of
membrane proteins that form the intercellular tight junction
barrier in a variety of epithelia. These studies have provided
valuable insights into the renal tubular pathways that regulate
calcium reabsorption and predispose to hypercalciuria and
nephrolithiasis.
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Introduction
Nephrolithiasis (kidney stone disease), which is a com-
mon disorder that affects approximately 3–5% of the
population [1], is usually associated with a metabolic
abnormality that may include hypercalciuria, hyperphos-
phaturia, hyperoxaluria, hypocitraturia, hyperuricosuria,
cystinuria, a low urinary volume and a defect in urinary
acidification [2, 3]. If uncorrected, these metabolic
abnormalities may lead to recurrent stone formation,
whose rate may be as high as 50% at 5 years [4, 5]. The
etiology of these metabolic abnormalities and of renal
stones is multi-factorial and involves interactions between
environmental and genetic determinants [6–8]. The envi-
ronmental determinants include dietary intake of salt,
protein, calcium and other nutrients, fluid intake, urinary
tract infections, socio-economic status of the individual,
lifestyle and climate [9, 10]. This review will focus on the
progress made on the genetic determinants of hyper-
calciuric nephrolithiasis (Table 1), as these are more likely
to present in childhood.
Nephrolithiasis may affect children of all ages, with
preponderance for boys [11], but it is important to note that
children represent only 2–3% of the total population of
stone formers [12]. However, nephrolithiasis is associated
with a metabolic abnormality in approximately 50% of
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e-mail: rajesh.thakker@ndm.ox.ac.ukchildren. The younger child will likely present with
hematuria or urinary tract infection due to stones sited
predominantly in the kidney, whilst the adolescent child is
more likely to develop ureteric stones and classical renal
colic [13]. More than 75% of these children will have
stones composed of calcium phosphate or calcium oxalate
[14], approximately 25% will have an associated urinary
tract infection [15, 16] and 30% will have anatomical
abnormalities that include hydronephrosis, posterior ure-
thral valves and fused crossed renal ectopy [14]. The
affected children are at risk of chronic urinary tract
infections and progressive kidney disease, but treatment of
the metabolic abnormality and nephrolithiasis will help to
prevent these complications.
Genetic epidemiology of nephrolithiasis
and hypercalciuria
The greatest risk factor for nephrolithiasis, after controlling
for known dietary determinants, is having an affected
family member [17], and it has been known since the
1890s that patients with renal stones are more likely than
those that are not renal stone formers to have other family
members affected with nephrolithiasis [18]. Thus, between
35% and 65% of renal stone formers will have relatives
with nephrolithiasis, whereas only 5–20% of those that are
not renal stone formers will have relatives with nephroli-
thiasis [17, 19, 20]. The first degree relative risk (λ R)
amongst recurrent stone formers has been estimated to be
Table 1 Genetic defects associated with some monogenic forms of hypercalciuria
Disease
a Mode of inheritance
b Gene
c Human chromosomal
location
Reference
Idiopathic hypercalciuria
A-d SAC 1q23.3-q24 [35]
A-d VDR 12q12-q14 [30]
A-d ? 9q33.2-q34.2 [31]
ADHH A-d CASR 3q21.1 [40]
Hypercalcemia with hypercalciuria A-d CASR 3q21.1 [38]
Bartter syndromes
Type I A-r SLC12A1/NKCC2 15q15-q21.1 [90]
Type II A-r KCNJ1/ROMK 11q24 [91]
Type III
d A-r CLCNKB 1q36 [92]
Type IV
d A-r BSND 1q31 [93]
Type V A-d CASR 3q21.1 [48]
Type VI
e X-r CLCN5 Xp11.22 [50]
Dent’s disease X-r CLCN5 Xp11.22 [52]
Lowe’s syndrome X-r OCRL1 Xq25 [60]
HHRH A-r NPT2c/SLC34A3 9q34 [69]
Nephrolithiasis, osteoporosis and hypophosphatemia A-d NPT2a/SLC34A1 5q35 [64]
Familial hypomagnesemia with hypercalciuria
and nephrocalcinosis
A-r PCLN1/CLDN16 3q28 [73]
Familial hypomagnesemia with hypercalciuria
and nephrocalcinosis with ocular abnormalities
A-r CLDN19 1p34.2 [77]
dRTA A-d SLC4A1/kAE1 17q21.31 [81]
dRTA with sensorineural deafness A-r ATP6B1/ATP6V1B1 2p13 [85]
dRTA with preserved hearing A-r ATP6N1B/ATP6V0A4 7q34 [88]
aADHH autosomal dominant hypocalcemia with hypercalciuria, HHRH hereditary hypophosphatemic rickets with hypercalciuria, dRTA distal
renal tubular acidosis
bA-d autosomal dominant, A-r autosomal recessive, X-r X-linked recessive
cSAC human soluble adenylyl cyclase; VDR vitamin D receptor; CASR calcium-sensing receptor; SLC12A1 solute carrier family 12, member 1;
NKCC2 sodium–potassium–chloride co-transporter 2; KCNJ1 potassium channel, inwardly rectifying, subfamily J, member 1; ROMK renal outer
medullary potassium channel; CLCNKB chloride channel Kb; BSND Barttin; CLCN5 chloride channel 5; OCRL1 oculo-cerebro-renal syndrome of
Lowe 1; NPT2c/a sodium–phosphate co-transporter type 2c/a; SLC34A1/3 solute carrier family 34, member 1/3; PCLN1 paracellin; CLDN16/19
claudin 16/19; SLC4A1 solute carrier family 4, member 1; kAE1 kidney anion exchanger 1; ATP6B1 ATPase, H
+ transporting (vacuolar proton
pump), V1 subunit B1; ATP6N1B ATPase, H
+ transporting, lysosomal V0 subunit a4
dBartter type III is associated with hypercalciuria but not nephrocalcinosis; Bartter type IV is not associated with persistent hypercalciuria or
nephrocalcinosis, but these are included here for completeness
eBartter type VI has been reported in one patient only, who had hypercalciuria
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estimates is largely due to differences in the study designs
and the methods used to ascertain the occurrence of renal
stones in relatives. Moreover, studies of twins have shown
that the contributions of heritability to kidney stones and
urinary calcium excretion are as high as 56% and 52%,
respectively [23, 24].
Hypercalciuria, which is defined as a urinary calcium
excretion in excess of 0.1 mmol/kg per 24 h or 4 mg/kg per
24 h [25, 26] is the most common metabolic abnormality
associated with nephrolithiasis and is found in approxi-
mately 60% of patients with renal stones [2, 27]. Hyper-
calciuria may occur either as an isolated trait or in
association with other metabolic abnormalities, and also
as part of a renal tubular disorder. Up to 65% of patients
with hypercalciuric nephrolithiasis may have a family
history of the disorder [17, 19] and the inheritance may
occur as that of a polygenic quantitative trait, or of a
monogenic trait with either autosomal dominant, autosomal
recessive or X-linked recessive modes of transmission
(Table 1). The monogenic forms of hypercalciuric neph-
rolithiasis and their associated underlying molecular genetic
mechanisms that may be associated with defects of
intestinal calcium absorption, bone calcium resorption,
and renal calcium reabsorption will be reviewed (Table 1).
Monogenic forms of hypercalciuria with nephrolithiasis
Idiopathic hypercalciuria
Families with idiopathic hypercalciuria (IH) and recurrent
calcium oxalate stones usually reveal an autosomal domi-
nant mode of inheritance [28]. Studies of such families
have established linkage between hypercalciuric nephroli-
thiasis and loci on: chromosome 1q23.3-q24, which
contains the human soluble adenylyl cyclase (SAC) gene
[29]; chromosome 12q12-q14, which contains the
vitamin D receptor (VDR) gene [30]; and chromosome
9q33.2-q34.2, from which an appropriate candidate gene
remains to be identified [31].
Absorptive hypercalciuria locus on 1q23.3-q24
Absorptive hypercalciuria (AH), which is characterized by
increased intestinal calcium uptake, normocalcemia, normal
concentrations of circulating parathyroid hormone (PTH),
and low bone mineral density [32], may occur as an
autosomal dominant trait [33]. Linkage studies in three
families with AH, mapped the locus to chromosome
1q23.3-q24 [29] and to a region that contained a gene
encoding a human SAC, which is a divalent cation and
bicarbonate sensor [34]. The SAC protein, which does not
respond to the heterotrimeric G protein regulators, exists
freely in cytosolic and membrane-associated forms, and its
cyclase catalytic activity helps to facilitate the generation of
cyclic adenosine monophosphate (cAMP) in the vicinity of
its targets. Mutational analysis of SAC in patients with AH
revealed six sequence variations, and four of these were
shown to be associated with a significantly increased
relative risk for AH [35]. The manner in which these four
sequence variations of SAC result in hypercalciuria and
nephrolithiasis remains to be elucidated.
Vitamin D receptor and IH
Increased levels of VDR are found in circulating monocytes
from patients with IH [36], and studies in a cohort of large
French-Canadian families have revealed an association
between IH nephrolithiasis and polymorphic loci from
chromosome 12q12-q14, a region that contains the VDR
gene [30]. However, DNA sequence analysis of the VDR
gene did not identify any VDR mutations, but it did reveal
conservative substitutions within the coding region. The
role of these VDR polymorphisms in the etiology of IH
nephrolithiasis remains to be explained.
Chromosome 9q33.2-q34.2 locus for autosomal dominant
nephrolithiasis
A form of autosomal dominant nephrolithiasis (NPL1) has
been reported in a Spanish kindred that originated from La
Gomera, in the Canary Islands, and resides in Tenerife [31].
The renal stones were reported to consist of calcium
oxalate, and serum and urine analyses did not reveal any
significant abnormalities, although some affected members
had mild hypercalciuria and some had hypomagnesemia.
Linkage analysis mapped the NPL1 locus to chromosome
9q33.2-q34.2. This region contains approximately 170
genes, and, to date, the gene causing NPL1 has not been
identified [31].
Calcium-sensing receptor and hypercalciuric disorders
The human calcium-sensing receptor (CaSR) is a 1,078
amino acid cell surface protein, which is predominantly
expressed in the parathyroids and kidney and is a member
of the family of G protein-coupled receptors. The CaSR
allows regulation of PTH secretion and renal tubular
calcium reabsorption in response to alterations in extracel-
lular calcium concentrations. The human CASR gene is
located on chromosome 3q21.1, and loss-of-function CaSR
mutations have been reported in the hypercalcemic disor-
ders of familial benign (hypocalciuric) hypercalcemia
(FBHH), neonatal severe primary hyperparathyroidism
(NSHPT) and familial isolated hyperparathyroidism
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in autosomal dominant hypocalcemia with hypercalciuria
(ADHH) and Bartter’s syndrome type V.
Familial isolated primary hyperparathyroidism due
to CaSR mutations
Hereditary disorders associated with hypercalcemia in-
clude familial isolated primary hyperparathyroidism
(FIHP), familial benign hypocalciuric hypercalcemia
(FBHH), multiple endocrine neoplasia type 1 (MEN1),
MEN type 2 (MEN2), and the hyperparathyroidism–jaw
tumor (HPT-JT) syndrome. The hypercalcemia of FIHP,
MEN1, MEN2, and HPT-JT (Table 2) is associated with
hypercalciuria and sometimes kidney stones, whereas that
of FBHH is associated with a low urinary calcium–
creatinine clearance ratio (<0.01). In FBHH, which is an
autosomal dominant disorder, the hypercalcemia is usually
mild to moderate, i.e. within 10% of the upper limit of
normal, although some patients do have more severe
hypercalcemia [37]. Other biochemical features include
mild hypermagnesemia and normal or mildly elevated
serum PTH concentrations. FBHH is due to inactivating
mutations of the CASR gene, which is located on
chromosome 3q21.1, whereas the genes causing MEN1,
M E N 2a n dH P T - J Ta r el o c a t e do nc h r o m o s o m e s1 1 q 1 3 ,
10q11.2, and 1q31.2, respectively. Some patients with
FIHP have mutations of the MEN1, HPT-JT and CaSR
genes, although the majority of FIHP patients do not have
such mutations and the genes involved need to be
characterized. Five CaSR mutations (Thr100Ile, Lys336-
deletion, Leu650Pro, Val689Met and Phe881Leu) have
been reported in FIHP [38, 39]. Functional characteriza-
tion of the mutant Phe881Leu CaSR only, has been
undertaken in HEK293 cells, and this demonstrated that
the Phe881Leu mutation resulted in a loss of function [38].
Thus, although the majority of loss-of-function CaSR
mutations will lead to FBHH, some may result in
hypercalcemic adenoma formation.
Autosomal dominant hypocalcemic hypercalciuria
Patients with ADHH usually have mild hypocalcemia that
is generally asymptomatic, but it may, in some patients, be
associated with carpo-pedal spasm and seizures [40]. The
serum phosphate concentrations in patients with ADHH
are either elevated or in the upper–normal range, and the
serum magnesium concentrations are either low or in the
low–normal range [40]. These biochemical features of
hypocalcemia, hyperphosphatemia and hypomagnesemia
are consistent with hypoparathyroidism and pseudo-hypo-
parathyroidism. However, these patients have serum PTH
concentrations that are in the low–normal range [40–44].
Thus, they are not hypoparathyroid, which would be
associated with undetectable serum PTH concentrations,
or pseudo-hypoparathyroid, which would be associated
with elevated serum PTH concentrations. These patients
were therefore classified as having autosomal dominant
hypocalcemia (ADH) [41], and the association of hyper-
calciuria with this condition led to its being referred to as
autosomal dominant hypocalcemia with hypercalciuria
(ADHH) [40]. Treatment with active metabolites of
vitamin D to correct the hypocalcemia has been reported
to result in marked hypercalciuria, nephrocalcinosis,
nephrolithiasis and renal impairment, which was partially
reversible after cessation of the vitamin D treatment [40].
Thus, it is important to identify and restrict the use of
vitamin D treatment in such ADHH patients and their
families whose hypocalcemia is due to a gain-of-function
CaSR mutation and not hypoparathyroidism [40]. More
than 40 different CASR mutations have been identified in
ADHH patients, and over 50% of these are in the
extracellular domain [40–45]. Almost every ADHH family
has its own unique missense heterozygous CASR mutation
[45]. Studies of the expression of ADHH-associated CaSR
mutations have demonstrated a gain-of-function, whereby
there is a leftward shift in the dose–response curve, such
that the extracellular calcium concentration needed to
produce a half-maximal effective concentration (EC50)
Table 2 Hereditary diseases associated with hypercalcemia and hypercalciuria (FIHP familial isolated hyperparathyroidism, MEN multiple
endocrine neoplasia, HPT-JT hyperparathyroidism–jaw tumor syndrome)
Disorder Clinical features Gene product Chromosomal location of the gene
FIHP Familial isolated parathyroid tumors Menin 11q13
Parafibromin 1q31.2
CaSR 3q21.1
MEN1 Parathyroid hyperplasia and/or tumors associated with pituitary and
pancreatico-duodenal neuro-endocrine tumors
Menin 11q13
MEN2a Parathyroid tumors with medullary thyroid cancer and pheochromocytoma Ret 10q11.2
HPT-JT Parathyroid tumors with ossifying fibromas of the jaw Parafibromin 1q31.2
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trisphosphate, IP3) is significantly lower than that required
for the wild-type receptor [40, 41].
Bartter syndrome type V
Bartter syndrome is a heterogeneous group of autosomal
hereditary disorders of electrolyte homeostasis character-
ized by hypokalemic alkalosis, renal salt wasting that may
lead to hypotension, hyperreninemic hyperaldosteronism,
increased urinary prostaglandin excretion, and hypercalciu-
ria with nephrocalcinosis [46, 47]. Mutations of several ion
transporters and channels have been associated with Bartter
syndrome, and six types (Table 1) are now recognized [47].
Thus, type I is due to mutations involving the bumetanide-
sensitive sodium–potassium–chloride co-transporter
(NKCC2 or SLC12A1); type II is due to mutations of the
renal outer-medullary potassium (ROMK) channel; type III
is due to mutations of the voltage-gated chloride channel,
CLC-Kb; type IV is due to mutations of barttin, which is a
beta sub-unit that is required for trafficking of CLC-Kb and
CLC-Ka, and this form is also associated with deafness as
barttin, CLC-Ka and CLC-Kb are also expressed in the
marginal cells of the scala media of the inner ear that
secrete potassium ion-rich endolymph; and type V is due to
activating mutations of the CaSR. Patients with Bartter
syndrome type V have the classical features of the
syndrome, i.e. hypokalemic metabolic alkalosis, hyper-
reninemia and hyperaldosteronism [48, 49]. In addition,
they develop hypocalcemia, which may be symptomatic
and lead to carpo-pedal spasm, and an elevated fractional
excretion of calcium, that may be associated with neph-
rocalcinosis [48, 49]. Such patients have been reported to
have heterozygous gain-of-function CaSR mutations, and in
vitro functional expression of these mutations not only
revealed a leftward shift in the dose–response curve for the
receptor, but also showed them to have a much lower EC50
than that found in patients with ADHH [47–49]. This
suggests that the additional features that occur in Bartter
syndrome type V when compared to ADHH are due to
severe gain-of-function mutations of the CaSR [47]. Bartter
syndrome type VI has been reported in one child from
Turkey [50] and was associated with a CLCN5 mutation;
the latter are usually seen in Dent’s disease (see below).
Dent’s disease
Dent’s disease is an X-linked recessive renal tubular
disorder characterized by low molecular weight proteinuria,
hypercalciuria, nephrocalcinosis, nephrolithiasis, and even-
tual renal failure [51]. Dent’s disease is also associated with
the other multiple proximal tubular defects of the renal
Fanconi syndrome, which include aminoaciduria, phospha-
turia, glycosuria, kaliuresis, uricosuria, and impaired uri-
nary acidification [51]. With the exception of rickets, which
occurs in a minority of patients, there appear to be no extra-
renal manifestations in Dent’s disease [51]. The gene
causing Dent’s disease, CLCN5, encodes the chloride/
proton antiporter CLC-5 [52]. CLC family members, which
are usually voltage-gated chloride channels, have important
diverse functions that include the control of membrane
excitability, transepithelial transport and regulation of cell
volume [53]. CLC-5, which is predominantly expressed in
the kidney and, in particular, the proximal tubule, thick
ascending limb of Henle, and the alpha intercalated cells of
the collecting duct, has been reported to be critical for
acidification in the endosomes that participate in solute re-
absorption and membrane recycling in the proximal tubule
[54, 55]. CLC-5 is also known to alter membrane
trafficking via the receptor-mediated endocytic pathway
that involves megalin and cubulin [56]. CLC-5 mutations
associated with Dent’s disease impair chloride flow and
likely lead to impaired acidification of the endosomal
lumen and, thereby, also disrupt trafficking of endosomes
back to the apical surface [56]. This will result in
impairment of solute reabsorption by the renal tubule and
in the defects observed in Dent’s disease [57]. Mice that are
deficient for CLC-5 develop the phenotypic abnormalities
associated with Dent’s disease [57]. Mutations of the gene
encoding an inositol polyphosphate 5-phosphatase result in
Lowe syndrome (see below) and also Dent’s disease [58].
Oculo-cerebro-renal syndrome of Lowe
The oculo-cerebro-renal syndrome of Lowe (OCRL) is an
X-linked recessive disorder that is characterized by
congenital cataracts, mental retardation, muscle hypoto-
nia, rickets, and defective proximal tubular reabsorption
of bicarbonate, phosphate and amino acids. Some patients
may also develop hypercalciuria and renal calculi [59].
The disease is nearly always confined to boys, who
develop renal dysfunction in the first year of life, have
delayed bone age and reduced height, and may die in
childhood. Female carriers who have normal neurological
and renal function can be identified in 80% of cases by
micro-punctate cortical lens opacities. The Lowe syn-
drome gene, OCRL1, is located on Xq25 and encodes a
member of the type II family of inositol polyphosphate 5-
phosphatases [60]. These enzymes hydrolyze the 5-
phosphate of inositol 1,4,5-trisphosphate and of inositol
1,3,4,5-tetrakisphosphate, phosphatidylinositol 4,5-
bisphosphate, and phosphatidylinositol 3,4,5-trisphos-
p h a t e ,t h e r e b yp r e s u m a b l yi n a c t i v a t i n gt h e ma ss e c o n d
messengers in the phosphatidylinositol signaling pathway
[61]. The preferred substrate of OCRL1 is phosphatidyli-
nositol 4,5-bisphosphate, and this lipid accumulates in the
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syndrome [61]. OCRL1 is localized to lysosomes in renal
proximal tubular cells and to the trans-Golgi network in
fibroblasts. This localization is consistent with the role of
OCRL1 in lysosomal enzyme trafficking from the trans-
Golgi network to lysosomes, and the activities of several
lysosomal hydrolases are found to be elevated in the
plasma of affected patients [62]. OCRL1 has also been
shown to interact with clathrin and indeed co-localizes
with clathrin on endosomal membranes that contain
transferrin and mannose 6-phosphate receptors [63].
Mannose 6-phosphate receptor-bound lysosomal enzymes
are recruited by appendage (AP) subunits and Golgi-
localized binding proteins into clathrin-coated vesicles that
t r a n s p o r tt h e mf r o mt h et r a n s - Golgi network to endosomes
[63]. Thus, it seems likely that the OCRL1 mutations in
Lowe syndrome patients result in OCRL1 protein defi-
ciency, which leads to disruptions in lysosomal trafficking
and endosomal sorting. This abnormality is similar to that
observed in Dent’s disease, and it is of interest to note that
some patients with the latter disease, who had no
demonstrable CLC-5 mutations, were found instead to
have OCRL1 mutations [58]. The absence of cataracts in
patients with Dent’sd i s e a s ed u et oOCRL1 mutations was
the major phenotypic difference found when such patients
were compared with patients with Lowe syndrome [58].
The molecular and cellular basis of these phenotypic
differences still remains to be elucidated.
Hereditary hypophosphatemic rickets with hypercalciuria
Two different heterozygous mutations (Ala48Phe and
Val147Met) in NPT2a (also referred to as SLC34A1), the
gene encoding a sodium-dependent phosphate transporter,
have been reported in patients with urolithiasis or osteopo-
rosis and persistent idiopathic hypophosphatemia due to
decreased phosphate reabsorption by the renal tubules [64].
When expressed in Xenopus laevis oocytes, the mutant
NPT2a showed impaired function. However, these in vitro
findings were not confirmed in another study using oocytes
and opossum kidney (OK) cells, raising the concern that the
NPT2a mutation identified could not explain the findings in
the patients described [65]. However, homozygous ablation
of Npt2a in mice (Npt2a-/-) results in increased urinary
phosphate excretion, hypophosphatemia, an appropriate
elevation in the serum levels of 1,25-dihydroxyvitamin D,
hypercalcemia, decreased serum parathyroid hormone
levels, increased serum alkaline phosphatase activity and
hypercalciuria (see below) [66]. Some of these biochemical
features are observed in patients with hereditary hypophos-
phatemic rickets with hypercalciuria (HHRH), but there are
important differences [67]. Thus, HHRH patients develop
rickets, short stature, with an increased renal phosphate
clearance, hypercalciuria, but have normal serum calcium
levels, increased gastrointestinal absorption of calcium and
phosphate due to an elevated serum concentration of 1,25-
dihydroxyvitamin D, suppressed parathyroid function and
normal urinary cAMP excretion [67]. However, HHRH
patients do not have NPT2a mutations [68], and studies
have demonstrated that HHRH patients harbor homozygous
or compound heterozygous mutations of SLC34A3, the
gene encoding the sodium–phosphate co-transporter NPT2c
[69, 70]. These findings indicate that NPT2c has a more
important role in phosphate homeostasis than was previ-
ously thought.
Familial hypomagnesemia with hypercalciuria
and nephrocalcinosis due to paracellin-1 (claudin 16)
mutations
Familial hypomagnesemia with hypercalciuria and neph-
rocalcinosis (FHHNC) is an autosomal recessive renal
tubular disorder that is frequently associated with progres-
sive kidney failure [71]. FHHNC often presents in
childhood, with seizures, or tetany due to hypocalcemia
and hypomagnesemia. Other recurrent clinical manifesta-
tions include urinary tract infections, polyuria, polydipsia,
and failure to thrive. Investigations reveal hypomagnese-
mia, hypocalcemia, hyperuricemia, hypermagnesuria,
hypercalciuria, incomplete acidification in the distal renal
tubules, hypocitraturia and renal calcification [72]. Treat-
ment consists of high doses of magnesium, administered
enterally, to restore normomagnesemia. Children with
FHHNC who receive such treatment early, develop nor-
mally. Studies of linkage in 12 FHHNC kindreds found the
disease locus to be on chromosome 3q27, and positional
cloning studies identified mutations in the gene encoding
paracellin-1 (PCLN-1), which is also referred to as
claudin 16 (CLDN16)[ 72]. FHHNC patients were either
homozygotes or compound heterozygotes for PCLN-1
mutations, consistent with the autosomal recessive inheri-
tance of the disorder [73]. The PCLN-1 mutations consisted
of premature termination codons, splice-site mutations and
missense mutations [72–74]. The PCLN-1 protein, which
consists of 305 amino acids, has sequence and structure
similar to those of the members of the claudin family and
is, therefore, also referred to as CLDN16 [72]. Claudins are
membrane-bound proteins that form the intercellular tight
junction barrier in a variety of epithelia [75]. Claudins have
four transmembrane domains and intracellular amino- and
carboxy-termini. The two luminal loops mediate cell–cell
adhesion via homo- and hetero-typic interactions with
claudins on a neighboring cell. In addition, claudins form
paracellular ion channels, which facilitate renal tubular
paracellular transport of solutes [75]. CLDN16 is exclu-
sively expressed in the thick ascending limb of Henle’s
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driven by an electrochemical gradient and allow reabsorp-
tion of calcium and magnesium [76]. Hence, loss of
function of CLDN16 that would arise from FHHNC
mutations would result in urinary calcium and magnesium
loss and lead to hypocalcemia and hypomagnesemia,
respectively. A CLDN16 missense mutation (Thr233Arg)
has also been identified in two families with self-limiting
childhood hypercalciuria [74]. The hypercalciuria decreased
with age and was not associated with progressive renal
failure. The Thr233Arg mutation resulted in inactivation of
a PDZ-domain binding motif, and this disrupted the
association with the tight junction scaffolding protein, zona
occludens (ZO)-1 [74], with accumulation of the mutant
CLDN16 protein in lysosomes and no localization to the
tight junctions. Thus, CLDN16 mutations may result in
different abnormalities in the function of renal tubular cells
and, hence, lead to differences in the clinical phenotype. A
form of FHHNC with severe ocular involvement reported
in one Swiss and eight Spanish/Hispanic families was
recently mapped to chromosome 1p34.2 [77]. This region
contains CLDN19, the gene that encodes claudin 19, a
tight-junction protein expressed in the kidney and eye. A
Gly20Asp mutation located in the first transmembrane
domain of CLDN19 was identified in all but one of the
Spanish/Hispanic families, and a Gln57Glu mutation in the
first extracellular loop of CLDN19 was found in the Swiss
family. In addition, a Leu90Pro mutation in CLDN19 was
identified in a consanguineous family of Turkish origin
with FHHNC and severe ocular involvement [77].
Distal renal tubular acidosis
In distal renal tubular acidosis (dRTA) the tubular
secretion of hydrogen ions in the distal nephron is
impaired, and this results in a metabolic acidosis that is
often associated with hypokalemia due to renal potassium
wasting, hypercalciuria with nephrocalcinosis, and meta-
bolic bone disease. Distal RTA may be familial, with
autosomal dominant or recessive inheritance. One form of
autosomal dominant dRTA is due to mutations of the
erythrocyte anion exchanger (band 3, AE1). Two autoso-
mal recessive forms of dRTA are caused by mutations of
sub-units of the H
+-ATPase (proton) pump. Thus, dRTA
associated with sensorineural deafness is associated with
mutations of the gene encoding the B1 subunit of the
apical H
+-ATPase pump (referred to as ATP6B1 or
ATP6V1B1), whilst dRTA without deafness is caused by
 
 
 
 
Child with hypercalciuria  
(24 hr urine calcium >0.1mmol/kg)
Measure plasma calcium and PTH 
PTH low  
Consider 
hypoparathyroidism
a 
PTH normal or low 
normal 
 
Suggestive of 
Autosomal dominant 
hypocalcemic 
hypercalciuria 
(ADHH) 
Hypocalcemic 
Assess plasma 
magnesium – if low 
consider familial 
hypomagnesemia with 
hypercalciuria and 
nephrocalcinosis or 
Claudin 19 mutation 
PTH raised 
 
Normocalcemic 
Renal Fanconi 
syndrome 
Low plasma 
phosphate with 
renal phosphate 
wasting 
Hypokalemic, 
hypochloremic 
metabolic acidosis 
and urinary pH>6 
Hypokalemic 
metabolic alkalosis  
Consider a 
diagnosis of Dent's 
disease or Lowe 
syndrome 
 
Consider diagnosis 
of hereditary 
hypophosphatemic 
rickets with 
hypercalciuria 
Consider a 
diagnosis of dRTA 
Consider a 
diagnosis of Bartter 
syndrome  
Consider the rare 
occurrence of a 
parathyroid tumor in 
FBHH 
 
Hypercalcemic 
PTH raised  
 
Consider a diagnosis 
of MEN1, HPT-JT or 
Familial isolated 
hyperparathyroidism 
PTH normal or low 
normal. 
Assess for plasma potassium, phosphate, bicarbonate, chloride and pH, and assess urine for 
phosphaturia, glycosuria, pH, low molecular weight proteinuria and aminoaciduria 
Fig. 1 Suggested algorithm for the investigation of a child with
hypercalciuria and nephrolithiasis/nephrocalcinosis, based initially on
measurements of plasma calcium and PTH. For the hypocalcemic
patient, hypoparathyroidism in this context, i.e. in association with
hypercalciuria, is rare and is included here for completeness. One
study of 85 patients with hypoparathyroidism and 15 ADHH patients
has shown that prior to their treatment with vitamin D to correct the
hypocalcemia, the urinary calcium/creatinine ratio in ADHH patients
was generally higher than that found in patients with hypoparathy-
roidism, although there was an overlap [94]. Following treatment with
vitamin D, the urinary calcium/creatinine ratios in ADHH and
hypoparathyroid patients were similar [94]. Hence, it may be difficult
for patients with hypoparathyroidism to be distinguished from those
with ADHH on the sole basis of urinary calcium excretion evaluations
[94]
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ATP6N1B (also referred to as ATP6V0A4), which is an
isoform of ATP6N1A that is the 116 kDa non-catalytic
accessory subunit of the proton pump.
Autosomal dominant dRTA due to erythrocyte anion
exchanger (Band 3) mutations
The family of anion exchangers (AEs) is widely distributed
and involved in the regulation of trans-cellular transport of
acid and base across epithelial cells, cell volume and
intracellular pH [78]. For example, AE1, which is a major
glycoprotein of the erythrocyte membrane, mediates ex-
change of chloride and bicarbonate [79]. AE1 is also found
in the basolateral membrane of the α-intercalated cells of
renal collecting ducts, which are involved in acid secretion
[80]. Patients with autosomal dominant dRTA, the majority
of whom had hypercalciuria, renal stones and nephrocalci-
nosis and a few of them who had erythrocytosis, were
found to have AE1 mutations [81]. These AE1 mutations
resulted in several functional abnormalities that included
reductions in chloride transport, and trafficking defects that
led to cellular retention of AE1 or mis-targeting of AE1 to
the apical membrane [82, 83]. AE1 mutations may also be
associated with autosomal recessive dRTA in Southeast
Asian kindreds that have ovalocytosis [84].
Autosomal recessive distal renal tubular acidosis due
to proton pump mutations
Proton pumps (H
+-ATPase) are ubiquitously expressed, and
one such multi-unit H
+-ATPase is found in abundance on
the apical (luminal) surface of the α-intercalated cells of the
cortical collecting duct, which regulates urinary acidifica-
tion. Failure of vectorial proton transport by these α-
intercalated cells results in the duct’s inability to acidify the
urine and in disorders of dRTA. The molecular basis of two
types of autosomal recessive dRTA due to proton pump
abnormalities has been characterized. The gene causing one
type of autosomal recessive dRTA that was associated with
sensorineural hearing loss was mapped to chromosome
2p13, which contained the ATP6B1gene that encodes the
B1 subunit of the apical proton pump (H
+ATPase) [85].
Mutations that would likely result in a functional loss of
ATP6B1 were identified in over 30% of families with this
form of autosomal recessive dRTA that occurred with
deafness in >85% of families [85]. The association of
dRTA and deafness is consistent with the renal and cochlear
expression of ATP6B1 [86, 87]. ATP6B1 plays a critical
role in regulating the pH of the inner ear’s endolymph, and
dysfunction of this would lead to an alkaline micro-
environment in the inner ear, which has been proposed to
impair hair cell function and result in progressive deafness
[85, 87]. The gene causing autosomal recessive dRTA with
normal hearing was localized to chromosome 7q33-q34,
which contained the ATP6N1B gene that encodes the non-
catalytic accessory subunit of the proton pump of the
α-intercalated cells of the collecting duct [88]. ATP6N1B
mutations, which are predicted to result in a functional loss,
were identified in >85% of kindreds with autosomal
recessive dRTA associated with normal hearing, and this
is consistent with the expression of ATP6N1B in the kidney
and not other organs. Approximately 15% of families with
autosomal recessive dRTA were not found to have
mutations in ATP6B1 or ATP6N1B mutations, and this
indicates that mutations in other genes are likely to be
involved in the etiology of autosomal recessive dRTA [89].
Conclusions
Although kidney stones are an infrequent occurrence in
children, they are, nevertheless, important causes of
abdominal pain, urinary tract infection and progressive
renal failure. Renal stones in children are associated with a
metabolic abnormality in approximately 50% of patients,
and treatment of this will help to prevent long-term
complications. Thus, the investigation of hypercalciuric
nephrolithiasis requires an assessment for these metabolic
abnormalities, and a measurement of plasma and urinary
electrolytes and metabolites is of importance. An approach
to the diagnosis of these complex disorders, based upon the
assessment of plasma calcium and PTH in a child with
hypercalciuria, is outlined in Fig. 1. These metabolic
disorders are often inherited and associated with hyper-
calciuria (Table 1), and studies of these disorders have
elucidated some of the renal tubular transport mechanisms
that regulate calcium reabsorption.
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Questions
(Answers appear after the reference list)
1. Which of the following does NOT constitute a major
risk factor for the development of kidney stones in
children?
2328 Pediatr Nephrol (2009) 24:2321–2332a. Anatomical abnormalities
b. Family history
c. Hypercalciuria
d. Urinary tract infection
e. Hypocalcemia
2. Which form of Bartter’s syndrome is NOT associated
with nephrocalcinosis?
a. Type I
b. Type II
c. Type III
d. Type V
e. Type VI
3. The Bartter syndromes are characterized by which of
the following clinical and biochemical features?
a. Hyperkalemia
b. Hypercalcemia
c. Metabolic alkalosis
d. It is always associated with an autosomal recessive
mode of transmission
e. It may be associated with a defect in anion
exchanger 1
4. Which of the following statements concerning idio-
pathic hypercalciuria (IH) is TRUE?
a. It is associated with 24-hour urinary calcium
excretion of <0.1mmol/kg
b. It may be associated with increased intestinal
absorption of calcium
c. Families with IH often have recurrent calcium
oxalate stones which have an autosomal recessive
mode of inheritance
d. Mutations in the vitamin D receptor is a common
cause of idiopathic hypercalciuria
5. Which of the following is NOT due to a mutation in the
CaSR gene?
a. FIHP
b. Bartter’s syndrome
c. ADHH
d. Dent’s disease
e. FBHH
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